

Onconova Therapeutics

ONTRAC stopped

Clinical update


Pharma & biotech

19 December 2013

Price **US\$13.3**
Market cap **US\$285m**

Net cash (\$m) as at Dec 2013e 99
 Shares in issue 21.4m
 Free float 21%
 Code ONTX
 Primary exchange NASDAQ
 Secondary exchange N/A

Share price performance



% 1m 3m 12m
 Abs 13.4 (46.7) N/A
 Rel (local) 12.2 (49.2) N/A
 52-week high/low US\$29.4 US\$11.8

Business description

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule drug candidates to treat cancer. Its lead drug candidate, rigosertib, is partnered with Baxter (Europe) and SymBio (Japan/Korea) and is in Phase III trials for higher-risk MDS (IV form), and in Phase II for lower-risk MDS (oral form).

Next events

Rigosertib Phase III MDS top-line data Q114
 Rigosertib NDA filing H214
 Rigosertib (oral) MDS reg. path decision 2014

Analysts

Jason Zhang PhD +1 646 653 7027
 Robin Davison +44 (0)20 3077 5737
healthcare@edisongroup.com
[Edison profile page](#)

Onconova has discontinued its Phase III ONTRAC trial of rigosertib (IV) in combination with gemcitabine (gem) vs gem alone as first-line treatment of pancreatic cancer, after the study failed a pre-planned interim analysis. We assigned no value to rigosertib in pancreatic cancer because of the specific challenges in this indication and hence the event does not change our valuation. This remains at \$476m, equivalent to \$22.3 per share basic (\$20.7/share, fully diluted), with our investment thesis centred on the potential of rigosertib in myelodysplastic syndromes (MDS). Top-line results from the ONTIME trial in high-risk MDS are due in Q114.

Year end	Revenue (\$m)	PBT* (\$m)	EPS* (\$)	DPS (\$)	P/E (x)	Yield (%)
12/11	1.5	(27.6)	(14.8)	0.0	N/A	N/A
12/12	46.2	(30.3)	(15.5)	0.0	N/A	N/A
12/13e	3.3	(68.5)	(8.9)	0.0	N/A	N/A
12/14e	50.0	(48.9)	(2.3)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

ONTRAC study discontinued after futility analysis

The Phase III ONTRAC trial was designed to enrol 650 patients with an interim analysis at 150 patients. The interim analysis concluded that the combination was unlikely to offer an improvement in overall survival and thus continuation of the trial would be futile. This comes as no surprise as many similar combinations (a new drug plus gem) have failed in Phase III trials for pancreatic cancer, with the notable exceptions of FOLFIRINOX [oxaliplatin, irinotecan, fluorouracil, and leucovorin] and Abraxane. Furthermore, even if a modest benefit had been shown, further studies would be required because the standard of care has now moved to Abraxane/gem.

Focus remains on MDS – ONTIME data in Q114

The termination of ONTRAC should be a blessing in disguise, since it will allow Onconova to focus on rigosertib in its two most promising indications: higher-risk MDS for the IV and lower-risk MDS for the oral form. If rigosertib (IV) meets its primary endpoint in the ONTIME Phase III trial in higher-risk, second-line MDS in Q114, Onconova could file its first NDA next year. We believe the 270 plus-patient trial has a good chance of delivering a positive outcome, based on our analysis of Phase I and II data. Additional data reported at the 2013 American Society of Hematology (ASH) also further confirmed the drug's activity and safety.

Valuation: Unchanged at \$476m

Our risk-adjusted DCF valuation remains unchanged at \$476m, or \$22.3 per basic share (\$20.7/share, fully diluted), because we previously assigned no value to the pancreatic cancer indication. Hence, the fall in the share price in response to the ONTRAC discontinuation could represent a buying opportunity. The ONTIME top line data is the next major valuation inflection point, which if positive would add significant value to our model.

Onconova datasheet

Exhibit 1: Onconova pipeline summary

Drug	Indication	Status	Notes
Rigosertib	Higher-risk MDS after HMA (IV)	Phase III top-line results Q114	Licensed to Baxter (total earnable payments of \$770m) for Europe, and Symbio (total earnable payments of \$71m) for Japan/Korea. Onconova retains all rights elsewhere (including in the US). Temple University is entitled to 25% of sub-licence fees from Baxter and Symbio and a low single-digit royalty on net sales.
	Lower-risk MDS (oral)	Phase II final results at ASH	
	Refractory head and neck cancer (oral)	Phase II single arm, first phase of 20 pts results: 2014	
ON 013105	Refractory lymphoma, solid tumours	Phase I (solid tumour)	Specific inhibitor of PLK2. Studies could resume in Q114.
Recilisib	Acute radiation syndrome	Phase I ongoing	Collaboration with the US Department of Defence for radiation-induced cytopenia. Expected to be licensed out early.

Source: Edison Investment Research. Notes: Only clinical stage assets shown.

Exhibit 2: Ongoing rigosertib clinical trials

Trial name	Patients	Treatment	Details
ONTIME (04-21)	MDS, Vidaza or Dacogen failure	Rig (CI, 3-d Q2W for eight cycles or Q4W after eight cycles) plus BSC vs BSC alone	290-pt Phase III , primary endpoint: OS. Start: Nov 2010; results: Q114
ONTARGET (09-05)	MDS, TD, low, Int-1 or trisomy 8 Int-2	Oral, 560mg BID for two wks Q3W	60-pt Phase II , single arm, Primary endpoint: Units of blood cell transfusions at wk 8. Start: May 2012; results: Oct 2014
09-08	MDS, AML and CML	Oral, various doses BID for three wks Q4W; plus Vidaza	40-pt Phase I/II , primary endpoints: safety. Trial start: Aug 2013. Results: Aug 2015
09-09	Squamous cell carcinoma, refractory	Oral, 560mg BID for two wks Q3W	80-pt Phase II , primary endpoint: ORR; trial start: March 2013. Results: Sept 2015
09-07	MDS, transfusion dependent, low, Int-1	Oral, 560mg BID for two wks Q3W	40 pt Phase II , primary endpoints: HI. Trial start: July 2013. Results: June 2015
04-24 (ONTIME)	MDS, failure after Vidaza or Dacogen, excess blasts	CI, 1,800mg/m ² for three days Q2W (eight cycles) or Q4W (after eight cycles)	90 pt Phase IIIB , primary endpoint: relationship btw Bm response and survival. Start: Aug 2013. Results Dec 2015

Source: Edison Investment Research, Clinicaltrials.gov

Exhibit 3: Competitive environment: approved or developmental drugs for lower and higher-risk MDS

Drug	Company	MOA	Main indication	Status	Route of admin.	Selected relevant data in higher and lower-risk MDS	Reference
Vidaza (azacitidine)	Celgene	HMA	High risk MDS	Approved in all major countries	IV and SC		N/A
Dacogen (decitabine)	Eisai/ Astex	HMA	High risk MDS; elderly AML	Approved in US for MDS, EU for elderly AML	IV	Phase I, n=36 Int-2/high MDS failed Vidaza, 7/36 (19.4%) ORR, incl. 3mCR and 2SD, med. OS 7.3 mos	ASH 2013 Abs#2796
Revlimid	Celgene	IMiDs	Low risk, 5q-; MM	Approved worldwide	Oral	Phase II plus pred., n=25 low/Int-1, non-5q- MDS, 5/23 (22%) RBC TI	ASH 2013 Abs#1506
SGL-110	Ostuka/ Astex	HMA	New or ref. MDS, AML	Phase II	SC	n=93, 74 AML, 19 MDS, 2 CR, 1CRp and 2CRi in AML; 2mCR, 3 HI-E, 1 HI-N and 1 HI-P in MDS (prior HMA)	ASH 2013 Abs#1548
ARRY-614	Array Biopharma	p38 MAPK and Tie2 inhibitor	Low/Int-1 MDS	Phase I	Oral, QD or BID	n=62, 12/54 evaluable and 9/31 on drug >16 wks had HI	ASH 2013 Abs#387
Sapacitabine	Cyclacel Pharma	Nucleoside analogue	Elderly MDS ref. to HMA	Phase II randomised	Oral, QD or BID	n=63; 2 CR, 2 CRp, and 5 major HI; med. OS 8.6-9.7 mos	ASH 2013 Abs#2752
Clolar (clofarabine)	Sanofi/ Genzyme	second-gen nucleoside analogue	rr ALL, AML etc	Approved for rr ALL	IV daily x5	Phase II w/ cytarabine, n=29, 8/24 (33%) CR/CRp/mCR, 4/24 (17%) had SD, med. OS 4.8 mos	ASH 2013 Abs#1525
Pracinostat (SB939)	MEI Pharma	HDAC inhibitor	New AML and MDS	Phase II	Oral, thrice weekly (TIW)	In pilot Phase II, MDS, w/aza, 7/9 (CR+CRi+PR) incl 7 CR	ASH 2012 ABS#3821
Telintra (TLK199)	Telik	Glutathione S-transferase Inh.	Lower risk MDS	Phase II	Oral	n=38 low/Int-1 MDS, 11 of 38 (29%) had HI-E; 3 of 11 (27%) had TI	Cancer. 2012, 118:2138-2147
Oral azacitidine (CC-486)	Celgene	HMA	Maintenance Rx in AMLw/ CR	Phase III	Oral	n=53 low/Int-1 MDS; 18/53 (34%) ORR, 13/53 (24.5%) HI, 12/30 (40%) TI>56 d, 7/30 (23.3%) TI>84 d	ASH 2012 Abs#424
Mocetinostat	Mirati Therap.	HDAC inhibitor	Int-2/high MDS	Phase I/II	Oral	n=66 AML and MDS, w/aza., 22 MDS (13/22 (59%, CR+CRi), 6/17 (35%) TI	ASH 2013 Abs#1550
Vosaroxin	Sunesis Pharm.	Nucleoside analogue	AML or MDS	Phase I/II	IV	Data in MDS pending	N/A

Source: Edison Investment Research. Note: IMiDs = immunomodulatory drugs.

Exhibit 4: Financial summary

	\$m	2011	2012	2013e	2014e
		IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS					
Revenue		1.5	46.2	3.3	50.0
Cost of Sales		0.0	0.0	0.0	0.0
Gross Profit		1.5	46.2	3.3	50.0
EBITDA		(27.9)	(44.7)	(77.8)	(58.5)
Operating Profit (before amort. and except.)		(27.6)	(22.3)	(69.0)	(50.1)
Intangible Amortisation		0.0	0.0	0.0	0.0
Exceptionals		1.3	0.4	(0.1)	(0.1)
Other		0.0	0.6	0.5	1.2
Operating Profit		(26.3)	(21.3)	(68.5)	(49.0)
Net Interest		(0.0)	(8.6)	0.0	0.0
Profit Before Tax (norm)		(27.6)	(30.3)	(68.5)	(48.9)
Profit Before Tax (FRS 3)		(26.3)	(29.9)	(68.5)	(49.0)
Tax		0.0	0.0	0.4	0.0
Profit After Tax (norm)		(27.6)	(30.3)	(68.1)	(48.9)
Profit After Tax (FRS 3)		(26.3)	(29.9)	(68.1)	(49.0)
Average Number of Shares Outstanding (m)		2.14	2.21	7.97	22.00
EPS - normalised (\$)		(14.79)	(15.51)	(8.86)	(2.34)
EPS - normalised fully diluted (\$)		(14.79)	(15.51)	(8.86)	(2.34)
EPS - (IFRS) (\$)		(12.30)	(13.55)	(8.54)	(2.23)
Dividend per share (c)		0.0	0.0	0.0	0.0
Gross Margin (%)		100.0	100.0	100.0	100.0
EBITDA Margin (%)		(1877.3)	(96.7)	(2339.8)	(117.1)
Operating Margin (before GW and except.) (%)		(1854.3)	(48.2)	(2075.9)	(100.2)
BALANCE SHEET					
Fixed Assets		0.6	0.6	(0.1)	1.3
Intangible Assets		0.0	0.0	0.0	0.0
Tangible Assets		0.6	0.6	(0.1)	1.3
Investments		0.0	0.0	0.0	0.0
Current Assets		3.8	83.3	105.9	59.0
Inventory		0.0	0.0	0.0	0.0
Accounts receivable, net		0.0	0.0	0.0	0.0
Cash and cash equivalents		2.7	81.5	99.0	59.0
Other		1.1	1.7	6.8	0.0
Current Liabilities		(12.1)	(25.4)	(17.4)	(21.2)
Creditors		(12.1)	(25.4)	(17.4)	(21.2)
Short term borrowings		0.0	0.0	0.0	0.0
Long Term Liabilities		(10.8)	(15.5)	(14.1)	(14.1)
Deferred revenue, long term		(10.7)	(15.4)	(14.0)	(14.0)
Other long term liabilities		(0.1)	(0.0)	(0.0)	(0.0)
Net Assets		(18.4)	43.0	74.3	25.0
CASH FLOW					
Operating Cash Flow		(14.2)	1.6	(62.5)	(39.3)
Net Interest		(0.0)	0.0	0.0	0.0
Tax		0.0	0.0	0.0	0.0
Capex		(0.2)	(0.3)	(0.6)	(0.3)
Acquisitions/disposals		0.0	0.0	0.0	0.0
Financing		9.8	77.5	79.7	0.5
Dividends		0.0	0.0	0.0	0.0
Net Cash Flow		(4.6)	78.8	16.5	(39.0)
Opening net debt/(cash)		(7.3)	(2.7)	(81.5)	(99.0)
HP finance leases initiated		0.0	0.0	0.0	0.0
Other		0.0	0.0	1.0	(1.0)
Closing net debt/(cash)		(2.7)	(81.5)	(99.0)	(59.0)

Source: Edison Investment Research, Onconova accounts

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial advisory services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Onconova Therapeutics and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2013. "FTSE" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.